Literature DB >> 26510845

Severe spontaneous vertebral fractures after denosumab discontinuation: three case reports.

B Aubry-Rozier1, E Gonzalez-Rodriguez2, D Stoll2, O Lamy2.   

Abstract

Osteoporosis treatments are usually given for a limited period of time in order to balance benefits and risks. We report three cases of postmenopausal women without any previous fragility fracture who presented severe spontaneous vertebral fractures after denosumab discontinuation. We think that the occurrence of these fractures could be explained by the severe rebound effect observed after denosumab discontinuation and that a consensus regarding the end of treatment with denosumab has to be defined.

Entities:  

Keywords:  Denosumab discontinuation; Osteoporotic fracture; Osteoporotic treatment duration

Mesh：

Substances：

Year:  2015        PMID： 26510845     DOI： 10.1007/s00198-015-3380-y

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN： 0937-941X            Impact factor:   4.507


  15 in total

1.  Effect of 1 year of discontinuation of raloxifene or estrogen therapy on bone mineral density after 5 years of treatment in healthy postmenopausal women.

Authors:  S J M Neele; R Evertz; G De Valk-De Roo; J C Roos; J C Netelenbos
Journal:  Bone       Date:  2002-04       Impact factor: 4.398

2.  Effect of discontinuation of estrogen, calcitriol, and the combination of both on bone density and bone markers.

Authors:  J Christopher Gallagher; Prema B Rapuri; Gleb Haynatzki; Jeff R Detter
Journal:  J Clin Endocrinol Metab       Date:  2002-11       Impact factor: 5.958

3.  Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass.

Authors:  Henry G Bone; Michael A Bolognese; Chui Kin Yuen; David L Kendler; Paul D Miller; Yu-Ching Yang; Luanda Grazette; Javier San Martin; J Christopher Gallagher
Journal:  J Clin Endocrinol Metab       Date:  2011-02-02       Impact factor: 5.958

4.  Global consensus statement on menopausal hormone therapy.

Authors:  T J de Villiers; M L S Gass; C J Haines; J E Hall; R A Lobo; D D Pierroz; M Rees
Journal:  Climacteric       Date:  2013-04       Impact factor: 3.005

5.  Rapid loss of hip fracture protection after estrogen cessation: evidence from the National Osteoporosis Risk Assessment.

Authors:  John Yates; Elizabeth Barrett-Connor; Suna Barlas; Ya-Ting Chen; Paul D Miller; Ethel S Siris
Journal:  Obstet Gynecol       Date:  2004-03       Impact factor: 7.661

Review 6.  How long should we treat?

Authors:  C Roux; K Briot
Journal:  Osteoporos Int       Date:  2014-03-26       Impact factor: 4.507

7.  Fracture risk remains reduced one year after discontinuation of risedronate.

Authors:  N B Watts; A Chines; W P Olszynski; C D McKeever; M R McClung; X Zhou; A Grauer
Journal:  Osteoporos Int       Date:  2007-10-16       Impact factor: 4.507

8.  The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT).

Authors:  Dennis M Black; Ian R Reid; Steven Boonen; Christina Bucci-Rechtweg; Jane A Cauley; Felicia Cosman; Steven R Cummings; Trisha F Hue; Kurt Lippuner; Peter Lakatos; Ping Chung Leung; Zulema Man; Ruvie Lou Maria Martinez; Monique Tan; Mary Ellen Ruzycky; Guoqin Su; Richard Eastell
Journal:  J Bone Miner Res       Date:  2012-02       Impact factor: 6.741

9.  The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study.

Authors:  S Papapoulos; K Lippuner; C Roux; C J F Lin; D L Kendler; E M Lewiecki; M L Brandi; E Czerwiński; E Franek; P Lakatos; C Mautalen; S Minisola; J Y Reginster; S Jensen; N S Daizadeh; A Wang; M Gavin; C Libanati; R B Wagman; H G Bone
Journal:  Osteoporos Int       Date:  2015-07-23       Impact factor: 4.507

10.  Discontinuation of denosumab and associated fracture incidence: analysis from the Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM) trial.

Authors:  Jacques P Brown; Christian Roux; Ove Törring; Pei-Ran Ho; Jens-Erik Beck Jensen; Nigel Gilchrist; Christopher Recknor; Matt Austin; Andrea Wang; Andreas Grauer; Rachel B Wagman
Journal:  J Bone Miner Res       Date:  2013-04       Impact factor: 6.741
View more
  36 in total

1.  Vertebral fractures cascade: potential causes and risk factors.

Authors:  H Che; V Breuil; B Cortet; J Paccou; T Thomas; L Chapuis; F Debiais; N Mehsen-Cetre; R M Javier; S Loiseau Peres; C Roux; K Briot
Journal:  Osteoporos Int       Date:  2018-12-05       Impact factor: 4.507

2.  Multiple clinical vertebral fractures following denosumab discontinuation.

Authors:  A D Anastasilakis; P Makras
Journal:  Osteoporos Int       Date:  2015-12-22       Impact factor: 4.507

Review 3.  The next step after anti-osteoporotic drug discontinuation: an up-to-date review of sequential treatment.

Authors:  Núria Guañabens; María Jesús Moro-Álvarez; Enrique Casado; Josep Blanch-Rubió; Carlos Gómez-Alonso; Guillermo Martínez Díaz-Guerra; Javier Del Pino-Montes; Carmen Valero Díaz de Lamadrid; Pilar Peris; Manuel Muñoz-Torres
Journal:  Endocrine       Date:  2019-04-08       Impact factor: 3.633

4.  No Increase in Fractures After Stopping Hormone Therapy: Results From the Women's Health Initiative.

Authors:  Nelson B Watts; Jane A Cauley; Rebecca D Jackson; Andrea Z LaCroix; Cora E Lewis; JoAnn E Manson; Joan M Neuner; Lawrence S Phillips; Marcia L Stefanick; Jean Wactawski-Wende; Carolyn Crandall
Journal:  J Clin Endocrinol Metab       Date:  2017-01-01       Impact factor: 5.958

5.  Clinical vertebral fractures following denosumab discontinuation.

Authors:  Stergios A Polyzos; Evangelos Terpos
Journal:  Endocrine       Date:  2016-07-08       Impact factor: 3.633

6.  Cancel the denosumab holiday.

Authors:  M R McClung
Journal:  Osteoporos Int       Date:  2016-03-01       Impact factor: 4.507

7.  Effects of Teriparatide, Denosumab, or Both on Spine Trabecular Microarchitecture in DATA-Switch: a Randomized Controlled Trial.

Authors:  Joy N Tsai; Linda A Jiang; Hang Lee; Didier Hans; Benjamin Z Leder
Journal:  J Clin Densitom       Date:  2017-06-16       Impact factor: 2.617

Review 8.  New anabolic therapies for osteoporosis.

Authors:  Salvatore Minisola; Cristiana Cipriani; Marco Occhiuto; Jessica Pepe
Journal:  Intern Emerg Med       Date:  2017-08-05       Impact factor: 3.397

9.  Effects of bone remodeling agents following teriparatide treatment.

Authors:  D Burkard; T Beckett; E Kourtjian; C Messingschlager; R Sipahi; M Padley; J Stubbart
Journal:  Osteoporos Int       Date:  2018-03-14       Impact factor: 4.507

10.  Multiple vertebral fractures following osteoporosis treatment discontinuation: a case-report after long-term Odanacatib.

Authors:  N Binkley; D Krueger; A E de Papp
Journal:  Osteoporos Int       Date:  2018-02-18       Impact factor: 4.507
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.